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T he three attempts at human liver replacement re-ported in 1963 1 followed 7 years of research involv-
ing organ preservation, surgical technique, and the physi-
ological interrelation of the liver with the pancreas and 
other intra-abdominal viscera. There were no means of 
pteventing rejection at the beginning, but at the end, 
the decision to go forward hinged on a strategy of immu-
nosuppression developed in 1962 that ultimately revolu-
tionized transplantation of all organs. 
The Genesis of the Idea 
Engraftment of an Extra Liver 
The first recorded mention of liver transplantation 
in either scientific or lay literature was in 1955, when 
C. Stuart Welch (Albany, Ny) described the transplanta-
tion of an auxiliary liver to the right paravertebral gutter 
of mongrel dogs. 2 It was then thought that the volume 
rather then the source of blood delivered to the liver 
through its double blood supply was the critical determi-
nant of normal hepatic homeostasis. Welch provided his 
allografts with a portal venous inflow of redirected host 
inferior vena caval blood. When they rapidly atrophied, 
he incorrectly ascribed this solely to rejection. 
The Relevance of Hepatotrophic Factors 
Between 1956 and 1958, at the University of 
Miami where I was a surgical resident, I had developed 
nontransplant dog models to test the hypothesis that the 
liver and pancreas cross-modulated. The first evidence 
suggesting that this was true came from studying the 
effect on insulin/carbohydrate metabolism of altering 
portal venous inflow with classical Eck or reverse Eck 
fistula in alloxan diabetic dogs. 3 One of the other proce-
dures developed for the investigation was total hepatec-
tomy,4 the first stage of orthotopic liver transplantation. 
Circumstances in Miami precluded further develop-
ment. However, orthotopic liver transplantation after 
host hepatectomy was performed a few days after I moved 
to Northwestern University (Chicago) in late June 1958 
and was performed once or twice a week throughout the 
rest of the summer. The poor performance of abnormally 
vascularized orthotopic livers 5 and the acute atrophy of 
Welch's auxiliary grafts were explained by the trans-
plants' lack of access to an unknown factor (suspected to 
be insulin) present in high concentration in portal venous 
blood.6 
Proving the insulin hypothesis and convincing skep-
tics that insulin was a true hepatic growth factor required 
nearly 15 years.7 At the end, however, a precise explana-
tion could be provided for the previously enigmatic 
pathophysiology of Eck's fistula. Eventually, the identi-
fication of a family of factors with insulin-like hepato-
trophic properties that controlled liver structure, func-
tion, and the capacity for regeneration defined the new 
field of hepatotrophic physiology.s 
OrthotopiC Liver Transplantation 
In 1956,]ack Cannon of the University of Califor-
nia, Los Angeles, was the first to report liver replacement, 
citing Welch's article as the stimulus for his work. Can-
non alluded to "several successful operations" . . . 
"without survival of the patient" [dogs} but with no 
details. 9 Definitive information came from the canine 
experiments at Northwestern University and indepen-
dently from the team of Francis D. Moore at the Peter 
Bent Brigham Hospital ("The Brigham," Boston). [0 In 
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contrast to the metabolic basis of the Chicago initiative, 
Moore's liver research was an offshoot of an institutional 
commitment to kidney transplantation that had begun 
a decade earlier. 
Because effective immune suppression was not yet 
available in either laboratory, it was possible to do little 
more than develop the operation and study the events of 
unaltered rejection. Between 1958 and early 1960, 31 
of these orthotopic procedures in dogs were performed 
in Boston 10 and 80 in Chicago. 5 All animals with survival 
of 4 or more days had histopathologic findings of allograft 
rejection. The technical principles that emerged from 
this collective experience were (1) the need for splanchnic 
venous blood for optimal portal revascularization, (2) core 
cooling of the allograft by infusion of chilled solutions 
into the portal vein as is practiced clinically today, and (3) 
decompression of the occluded splanchnic and systemic 
venous pools into the upper vena caval system through 
external venous bypasses during the anhepatic stage. 
In addition to liver transplantation alone, modifica-
tions had been added by the end of 1959, including 
the multivisceral engraftment procedures 11 that would 
be used successfl,.dly in patients three decades later with 
essentially no change. 
Movement to the Clinic 
The Advent of Immunosuppression 
Total body irradiation (TBI), adrenal cortical ste-
roids, and the myelotoxic drug 6-mercaptopurine (6-MP) 
were shown between 1953 and 1959 to modestly prolong 
skin allograft survival in several animal species. Using 
TBI, successful kidney transplantation from fraternal (di-
zygotic) twin donors was accomplished in patients at the 
Brigham in January 1959 and again 5 months later in 
Paris. Although the genetic barrier to transplantation 
finally had been breached in humans, liver transplant 
surgery still had no conceivable application. Preoperative 
conditioning of hepatic canine recipients with TBI in our 
hands precluded even perioperative, much less extended, 
survival. 
The drugs 6_Mp12 and its analogue, azathioprine, were 
viewed in a different light. Whereas kidney transplanta-
tion with long survival had never previously been 
achieved in mongrel dogs, approximately 5% of animals 
given one or the other of the new drugs by the En-
glishman Roy CaIne]) in collaboration with Joseph Mur-
ray at the Brigham14 lived longer than 100 days. The 
objective of exploiting hepatic replacement to treat hu-
man liver disease was settled on as a high priority during 
my discussions in June 1961 with William R. Waddell, 
who left the Massachusetts General Hospital to assume 
the chairmanship of surgery at the University of Colorado 
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5 months before I joined him from Chicago. A prerequi-
site would be establishment of a track record in renal 
transplantation. In the United States, this procedure was 
under formal development only at the Brigham and at 
the Medical College of Virginia (David Hume). Willard 
Goodwin's early program at UCLA had been placed on 
hold. 
Our clinical plans for both organs were shelved in 
January 1962. 'We had been following the tracks laid by 
the American kidney transplant pioneers and those in 
Paris (Rene Kuss and Jean Hamburger), only to eventu-
ally realize that we had joined them in a therapeutic cul-
de-sac. CaIne and Mutray recognized the unacceptable 
therapeutic margin of azathioprine alone and had system-
atically tested drug combinations in their dog model. 
When prednisone given from the time of surgery had no 
additive effect,13,14 they settled for clinical use on a triple-
drug cocktail of azathioprine, azaserine, and actinomycin 
C. The results were little different than with TBI. In 
fact, as late as March 1, 1963, the date of our first liver 
transplantation, only 6 recipients of kidney allografts in 
the world had survived 1 year or longer (1 in Boston and 
5 in Paris), all treated with TBL The longest surviving 
kidney recipient treated solely with azathioprine- or 6-
MP - based therapy from April 1960 to April 1962 15 was 
now 11 months postoperative, but we knew from contact 
with Murray that the patient had deteriorating renal 
function. 
An Empirical Treatment Strategy 
The experimental results in the Denver V A canine 
laboratory resembled those in Boston and Richmond un-
til the summer of 1962 when a reproducible significant 
observation was made. Delayed high doses of prednisone 
were shown to reliably reverse the kidney (and, in pilot 
studies, liver) rejection that usually developed under pri-
mary azathioprine therapy. Most of the dogs died of 
complications OIf steroid-induced peptic ulceration, but 
several lived for years after discontinuance of prednisone 
and even when azathioprine also was stopped. Using the 
"double-drug cocktail," the Colorado clinical kidney 
transplant program finally was opened in November 
1962. 
The first 10 cases were compiled rapidly and reported 
in the October 1963 issue of Surgery, Gynecology, and 
Obstetrics,16 preceding by 2 months the article on liver 
transplantation in the same journal. 1 Four of the 10 renal 
recipients survived 2:25 years including 2 who still bear 
the longest continuously functioning kidney allografts 
in the world after a third of a century. The first patients 
in the series had rerurned to a relatively unrestricted 
environment on reduced maintenance immunosuppres-
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sion. We suggested that a state of relative hostl graft 
nonreactivity had been accidentally but regularly induced 
by the renal allografts. The controversial, but as it turned 
out apposite, term "tolerance" (see later) was used to 
describe the change. This was the signal that triggered 
the liver trials. 
The first 3 patients entered were a moribund child 
with biliary atresia, a 48-year-old man with Laennec's 
cirrhosis and an unresectable hepatoma, and a 67 -year-
old man with a completely obstructing bile duct carci-
noma who had previously undergone bilateral above-knee 
amputations for peripheral vascular disease. Their high 
risk factors would preclude candidacy today. Although 
2 survived the surgery, they died after 22 and 7.5 days of 
pulmonary emboli that were suspected to have originated 
from the plastic tubes used for the veno-venous bypass. 
The Aftermath 
The Colorado kidney center mushroomed over-
night while the spark that had ignited it, liver trans-
plantation, was consigned by the end of 1963 to a self-
imposed 31/ryear worldwide moratorium after four more 
failures: two in Denver and one each in Boston and Paris. 
Three advances applicable to all organs were made during 
this period: (l) the purification and clinical introduction 
in 1966 of antilymphocyte globulin for use with azathio-
prine and prednisone in a triple-drug regimen 17; (2) pres-
ervation techniques that allowed livers to be stored ex 
vivo for 1-2 days; and (3) demonstration (with Paul 
Terasaki of UCLA) that the quality of donorlrecipient 
HLA matching had little association with kidney trans-
plant outcome. When the liver program was reopened 
in July 1967 during the 2-year fellowship of Carl Groth 
(Stockholm), multiple examples of prolonged liver recipi-
ent survival were produced. 18,1 9 
A second liver transplant program was founded in 
1968 by Roy CaIne of Cambridge University and fostered 
by a long-lasting interuniversity collaboration with the 
hepatologist Roger Williams at King's College Hospital, 
London. The American and English teams sustained each 
other for the next dozen years, joined in the early 1970s 
by Rudolph Pichlmayr in Hannover and by Henri Bis-
muth in Paris, always tantalizingly close to making liver 
transplantation a service. In Denver, 170 patients under-
went the procedure between 1963 and 1979. Although 
only 56 survived for 1 year, 25 were alive after 13-22 
years at the end of 1992/° and 19 remain today with 
follow-ups of 17 -27 years. 
Although the feasibility of liver transplantation was 
established, the results remained unacceptable until Sir 
Roy CaIne, who had presided over the preclinical devel-
opment of the thiopurine drugs in Boston nearly two 
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decades before, repeated the feat with cyclosporine and 
then reported the first clinical series that included 2 liver 
recipients. In another visit to the past, the full potential 
of the new drug was realized for transplantation of the 
kidney, liver, and eventually all organs when it was com-
bined with prednisone or used in triple-drug cocktails.21 
The stampede to develop extrarenal transplant centers 
began. Nine years later, expectations moved up another 
notch with the substitution of tacrolimus for 
cyclosporine. 22 
In Retrospect 
Most failed trials are doomed to be footnotes, if 
that much, in the pages of history. The 1963 liver trans-
plant article escaped obscurity because it was based on 
principles that were enduring. Aside from the manifold 
details of the difficult operation, including the role of 
and complications from veno-venous bypass, there al-
ready was accurate insight into the importance of hepato-
trophic physiology and into the cause and treatment of 
metabolic acidosis. The only nonsurgeon author, Kurt 
von Kaulla, anticipated the intraoperative coagulation 
disorders, monitored them with serial thromboelasto-
grams, and provided treatment with blood components 
and epsilon amino caproic acid (an analogue of the cur-
rently used aprotinine). Lessons from the research preced-
ing the clinical trial had long since cross-fertilized to 
kidney transplantation and eventually were exploited for 
all kinds of allografts: core cooling by infusion of chilled 
intravascular fluids, in situ procurement procedures that 
presaged the standard flexible procedures of today, and 
the intravascular techniques required for close-quarter 
anastomoses. 
However, none of the generically applicable advances, 
or all together, remotely approached in importance the 
realization in the summer of 1962 that rejection could 
be engineered into prolonged allograft and recipient sur-
vival by the strategic use of existing agents. The cyclic 
pattern of convalescence and the consequent achievement 
of allograft acceptance remained enigmatic until it was 
discovered in 1992 that long-surviving organ recipients 
had donor leukocyte chimerism in their blood, skin, 
lymph nodes, and other sites as long as three decades 
after transplantation. 2o,23 Then it could be seen that the 
prototypic postoperative events following transplantation 
of all organs were the product of a double immune reac-
tion: host-versus-graft (rejection) and graft-versus-host. 
Potentially tolerogenic "passenger leukocytes" of bone 
marrow origin including pluripotent stem cells had mi-
grated from organs and engrafted peripherally. This was 
the seminal mechanism of organ allograft acceptance, an 
insight that enlarged the runnel leading to the future. 
January 1997 
The epiphany ended the 35 years of speculation preceding 
it. 
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